Related Experiment Videos
[Evaluation of construction and expression shiga toxin2 A-luteinizing hormone releasing hormone recombinant toxin]
Ying Yue1, Xiao-wei Yu, Yu-huan Yue
1Department of Obstetrics and Gynecology, First Hospital Jilin University, Changchun 130021, China.
Objective:
The purpose is to construct shiga toxin2A-luteinizing hormone releasing hormone (Stx2A-LHRH) recombinant toxin which can kill cancer cells specifically and try to get a new target-binding drug.
Methods:
The fragment of Stx2A-LHRH DNA amplified by polymerase chain reaction (PCR) were cloned into plasmid pET-20b(+) vector. The recombinant plasmid pET-Stx2A-LHRH was constructed successfully and identified by endonucleases digestion and sequencing analysis then it was transformed to Escherichia coli BL21 (DE3) and expressed under the induction of isopropyl-beta-D-thiogalactopyranoside.
Results:
The result of sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel thin layer scanning proved a special band of a molecular weight of about 38,000, accounting for 10.32% of total amount of the supernatant protein. Stx2A-LHRH recombinant toxin can kill HeLa cells clearly.
Conclusion:
Stx2A-LHRH recombinant toxin may become a choice of target-binding drug in the future.
Insights
Researchers engineered a novel shiga toxin2A-luteinizing hormone releasing hormone (Stx2A-LHRH) recombinant toxin. This targeted therapy effectively eliminates cancer cells, showing promise as a new cancer treatment drug.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Developing targeted cancer therapies is crucial for improving treatment efficacy and reducing side effects.
- Recombinant toxins offer a promising strategy for selective cancer cell destruction.
Purpose of the Study:
- To construct a shiga toxin2A-luteinizing hormone releasing hormone (Stx2A-LHRH) recombinant toxin.
- To evaluate its potential as a targeted drug for cancer cell elimination.
Main Methods:
- Polymerase chain reaction (PCR) amplification of Stx2A-LHRH DNA fragment.
- Cloning into pET-20b(+) vector, transformation into E. coli BL21 (DE3), and expression.
- Identification via endonuclease digestion and sequencing, followed by protein analysis using SDS-PAGE.
Main Results:
- Successful construction and expression of the Stx2A-LHRH recombinant toxin.
- SDS-PAGE confirmed a distinct protein band of approximately 38,000 molecular weight.
- The recombinant toxin demonstrated significant cytotoxicity against HeLa cancer cells.
Conclusions:
- The Stx2A-LHRH recombinant toxin is effectively produced and exhibits cancer cell-killing properties.
- This engineered toxin holds potential as a future targeted-binding therapeutic agent for cancer treatment.